Join to access to all OVN content. Join for Free

Results for 'add-on cohorts'

Browse oncology articles matching add-on cohorts — expert analysis, clinical perspectives, and industry updates from across drug development and care delivery. Use the tabs above for podcasts, press releases, partners, and people for the same search.

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
OVN Avatar M. Ochoa de Olza, M. Oliva, C. Hierro I. Matos, J. Martin-Liberal, E. Garralda
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

immunotherapy, early-drug development, toxicology studies, dose determination

The classical development of drugs is being replaced by a seamless drug-development process. First-in-human trials now often include large expansion cohorts to quickly identify early signs of activity and achieve rapid regulatory approval. Intense competition among pharmaceutical companies and t…

Jun 26th • 26 mins read

Defining the role of real-world data in cancer clinical research: The position of the
OVN Avatar Robbe Saesen, Mieke Van Hemelrijck, Jan Bogaerts, Christopher M. Booth, Jan J. Cornelissen, Andre Dekker, Elizabeth A. Eisenhauer, André Freitas, Alessandro Gronchi, Miguel A. Hernán, Frank Hulstaert, Piet Ost, Petr Szturz, Helena M. Verkooijen, Michael W
Defining the role of real-world data in cancer clinical research: The position of the

real-world data, real-world evidence, randomised, pragmatic trials, cancer, clinical research, add-on cohorts

Real-World Data (RWD) are increasingly used in cancer clinical research as an alternative evidence source. RWD studies primarily involve observational data, which offer insights into real-world conditions but may have quality limitations. Some research questions necessitate Randomized Controlled…

Mar 20th • 10 mins read

The FDA Oncology Center of Excellence and Precision Medicine
OVN Avatar Kirsten B Goldberg, Gideon M Blumenthal, Amy E McKee and Richard Pazdur
The FDA Oncology Center of Excellence and Precision Medicine

Biomarkers, drugs, hematology, medicine, oncology, precision medicine, regulation

The FDA is exploring real-world evidence to enhance understanding of the long-term safety and efficacy of oncology drugs. Initiatives like the Information Exchange and Data Transformation initiative are building infrastructure for big-data analytics. Additionally, patient-focused programs aim to inc…

Nov 6th • 3 mins read

AI-powered real-world evidence: Strategically enhancing value and access
Partner Avatar Envision Pharma Group
AI-powered real-world evidence: Strategically enhancing value and access

Oncology, Clinical Development, Targeted Therapy, Immunotherapy, Genomic Profiling, CAR-T Cell Therapy, Precision Medicine

Real-world evidence (RWE) complements traditional randomized controlled trials by providing insights from diverse data sources, helping healthcare decision-makers with coverage, reimbursement, and treatment guidelines. Artificial intelligence (AI) and natural language processing (NLP) are pivotal…

Aug 22nd • 5 mins read

Related Topics

Meet Our Innovation Partners

Loading partners...